Tocilizumab (RoActemra®)

DRUG2 trials

Sponsors

Hospital Clinico Universitario de Santiago, Herlev Hospital

Conditions

ArthritisColitisGraves´ OphthalmopathySolid TumorThyroid Associated OphthalmopathiesThyroid Eye Disease

Phase 3

Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)

CompletedNCT01297699

Hospital Clinico Universitario de SantiagoGraves´ Ophthalmopathy, Thyroid Associated Ophthalmopathies, Thyroid Eye Disease

Start: 2012-03-31End: 2015-12-31Updated: 2016-01-20

Unknown Phase

Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms

CompletedNCT03601611

Herlev HospitalArthritis, Colitis, Solid Tumor

Start: 2019-01-01End: 2020-01-28Updated: 2020-04-21

Related Papers

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Journal for ImmunoTherapy of Cancer2023-06-0183 citations

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

Journal for ImmunoTherapy of Cancer2022-09-0162 citations

Tocilizumab for thyroid eye disease.

2018-11-2721 citations